Overview
- The Joint Economic Committee’s Democratic minority released the report Friday that found President Trump’s reported pharmaceutical holdings rose from a maximum of $1.7 million in 2024 to as much as $56.2 million by the end of 2025.
- The report says up to $39.1 million of those holdings were in companies that benefited from a Republican 2025 change expanding an 'orphan-drug' exclusion that delays or exempts some medicines from Medicare price negotiations.
- Committee analysis documents portfolio purchases of as much as $2.55 million on three dates before the president signed the 2025 bill, including up to $950,000 on July 1, 2025, and a separate purchase of up to $1 million in AbbVie stock in August 2025 after the law took effect.
- Researchers estimate the carveout could leave some Medicare patients, including people taking Keytruda or Opdivo, paying roughly $5,000 more a year than they would if Medicare negotiated prices for those drugs.
- The White House denies any ethics breach and says the president’s investments are independently managed, while Democrats and consumer advocates say the report intensifies scrutiny of drug-pricing promises and the partisan debate over policy and patient costs.